Do analysts recommend INCR or ACOG?

Alpha Cognition has a consensus target price of $16.00, suggesting a potential upside of 79.98%. Given Alpha Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings & valuation, INCR or ACOG?

InterCure has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.67 -$10.37M $0.03 32.00 Alpha Cognition $10.22M 18.94 -$20.67M -$1.35 N/A

Do analysts recommend INCR or SBTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is INCR or SBTX more profitable?

InterCure's return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Silverback Therapeutics N/A -29.62% -28.20%

Do analysts rate INCR or IMUX?

Immunic has a consensus price target of $47.57, suggesting a potential upside of 237.39%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immunic 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, INCR or IMUX?

InterCure has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InterCure $78.47M 0.67 -$10.37M $0.03 32.00 Immunic N/A N/A -$97.17M -$5.58 N/A

Is INCR or IMUX more profitable?

InterCure's return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Immunic N/A -220.75% -132.04%

Do analysts rate NERV or INCR?

Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 127.27%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NERV or INCR more profitable?

Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -34.07% InterCure N/A N/A N/A

Do analysts prefer DERM or INCR?

Journey Medical presently has a consensus price target of $13.00, indicating a potential upside of 101.86%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Journey Medical is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, DERM or INCR?

InterCure has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Journey Medical $61.86M 2.87 -$11.43M -$0.37 N/A InterCure $78.47M 0.67 -$10.37M $0.03 32.00

InterCure (INCR) Competitors

$0.96 -0.02 (-2.04%)

As of 08/10/2026 04:00 PM Eastern

Compare

INCR vs. ACOG, SBTX, IMUX, NERV, and DERM

Should you buy InterCure stock or one of its competitors? InterCure's main competitors and comparable companies include Alpha Cognition (ACOG), Silverback Therapeutics (SBTX), Immunic (IMUX), Minerva Neurosciences (NERV), and Journey Medical (DERM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InterCure compare to Alpha Cognition?

InterCure (NASDAQ:INCR) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Alpha Cognition had 3 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Alpha Cognition and 0 mentions for InterCure. Alpha Cognition's average media sentiment score of 0.40 beat InterCure's score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the news media.

Company	Overall Sentiment
InterCure	Neutral
Alpha Cognition	Neutral

InterCure has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.3, indicating that its share price is 130% more volatile than the broader market.

InterCure has higher revenue and earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.67	-$10.37M	$0.03	32.00
Alpha Cognition	$10.22M	18.94	-$20.67M	-$1.35	N/A

8.3% of InterCure shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

InterCure has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. InterCure's return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Alpha Cognition	-232.23%	-58.35%	-45.99%

Alpha Cognition has a consensus target price of $16.00, suggesting a potential upside of 79.98%. Given Alpha Cognition's stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

InterCure and Alpha Cognition tied by winning 8 of the 16 factors compared between the two stocks.

How does InterCure compare to Silverback Therapeutics?

InterCure (NASDAQ:INCR) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

8.3% of InterCure shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, InterCure's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Silverback Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

InterCure has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.67	-$10.37M	$0.03	32.00
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

InterCure has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

InterCure's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

Summary

InterCure beats Silverback Therapeutics on 8 of the 10 factors compared between the two stocks.

How does InterCure compare to Immunic?

InterCure (NASDAQ:INCR) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

InterCure has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Immunic has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

InterCure has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.67	-$10.37M	$0.03	32.00
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A

In the previous week, Immunic had 1 more articles in the media than InterCure. MarketBeat recorded 1 mentions for Immunic and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 equaled Immunic'saverage media sentiment score.

Company	Overall Sentiment
InterCure	Neutral
Immunic	Neutral

Immunic has a consensus price target of $47.57, suggesting a potential upside of 237.39%. Given Immunic's stronger consensus rating and higher probable upside, analysts plainly believe Immunic is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

8.3% of InterCure shares are owned by institutional investors. Comparatively, 51.8% of Immunic shares are owned by institutional investors. 5.5% of Immunic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Immunic	N/A	-220.75%	-132.04%

Summary

Immunic beats InterCure on 8 of the 14 factors compared between the two stocks.

How does InterCure compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

InterCure has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
InterCure	$78.47M	0.67	-$10.37M	$0.03	32.00

In the previous week, Minerva Neurosciences had 6 more articles in the media than InterCure. MarketBeat recorded 6 mentions for Minerva Neurosciences and 0 mentions for InterCure. Minerva Neurosciences' average media sentiment score of 1.01 beat InterCure's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Positive
InterCure	Neutral

Minerva Neurosciences has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market. Comparatively, InterCure has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-34.07%
InterCure	N/A	N/A	N/A

Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 127.27%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Minerva Neurosciences beats InterCure on 7 of the 13 factors compared between the two stocks.

How does InterCure compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

InterCure has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.87	-$11.43M	-$0.37	N/A
InterCure	$78.47M	0.67	-$10.37M	$0.03	32.00

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Journey Medical presently has a consensus price target of $13.00, indicating a potential upside of 101.86%. Given Journey Medical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Journey Medical is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. InterCure's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
InterCure	N/A	N/A	N/A

In the previous week, Journey Medical had 2 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for InterCure. Journey Medical's average media sentiment score of 0.00 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Journey Medical	Neutral
InterCure	Neutral

Journey Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, InterCure has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Summary

InterCure beats Journey Medical on 9 of the 15 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.59M	$11.84B	$7.02B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	32.00	788.51	269.19	24.72
Price / Sales	0.67	740.84	588.76	97.80
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	0.45	10.33	11.27	6.42
Net Income	-$10.37M	$2.77B	$3.45B	$347.03M
7 Day Performance	-0.30%	0.85%	1.92%	0.69%
1 Month Performance	-1.03%	-1.60%	-0.58%	-0.90%
1 Year Performance	-43.20%	183.25%	75.49%	21.87%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	1.2098 of 5 stars	$0.96 -2.0%	N/A	-36.0%	$53.59M	$78.47M	32.00	350	Gap Down
ACOG Alpha Cognition	3.8754 of 5 stars	$8.52 -4.7%	$16.00 +87.8%	-10.2%	$194.66M	$10.22M	N/A	N/A	Upcoming Earnings Gap Down
SBTX Silverback Therapeutics	N/A	$5.32 -2.6%	N/A	-64.8%	$191.83M	N/A	N/A	83	High Trading Volume
IMUX Immunic	2.9166 of 5 stars	$13.96 -0.6%	$47.57 +240.7%	+61.7%	$191.38M	N/A	N/A	70
NERV Minerva Neurosciences	1.7689 of 5 stars	$4.35 +7.7%	$10.50 +141.4%	+162.5%	$188.22M	N/A	N/A	9	Positive News Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. ACOG, SBTX, IMUX, NERV, and DERM

How does InterCure compare to Alpha Cognition?

Summary

How does InterCure compare to Silverback Therapeutics?

Summary

How does InterCure compare to Immunic?

Summary

How does InterCure compare to Minerva Neurosciences?

Summary

How does InterCure compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. ACOG, SBTX, IMUX, NERV, and DERM

How does InterCure compare to Alpha Cognition?

Does the media prefer INCR or ACOG?

Which has more risk and volatility, INCR or ACOG?

Which has higher earnings & valuation, INCR or ACOG?

Do insiders & institutionals hold more shares of INCR or ACOG?

Is INCR or ACOG more profitable?

Do analysts recommend INCR or ACOG?

Summary

How does InterCure compare to Silverback Therapeutics?

Do insiders and institutionals have more ownership in INCR or SBTX?

Does the media refer more to INCR or SBTX?

Do analysts recommend INCR or SBTX?

Which has preferable earnings & valuation, INCR or SBTX?

Which has more volatility & risk, INCR or SBTX?

Is INCR or SBTX more profitable?

Summary

How does InterCure compare to Immunic?

Which has more volatility & risk, INCR or IMUX?

Which has stronger valuation and earnings, INCR or IMUX?

Does the media favor INCR or IMUX?

Do analysts rate INCR or IMUX?

Do institutionals and insiders have more ownership in INCR or IMUX?

Is INCR or IMUX more profitable?

Summary

How does InterCure compare to Minerva Neurosciences?

Do institutionals and insiders hold more shares of NERV or INCR?

Which has better earnings & valuation, NERV or INCR?

Does the media prefer NERV or INCR?

Which has more risk & volatility, NERV or INCR?

Is NERV or INCR more profitable?

Do analysts rate NERV or INCR?

Summary

How does InterCure compare to Journey Medical?

Which has preferable earnings and valuation, DERM or INCR?

Do institutionals and insiders believe in DERM or INCR?

Do analysts prefer DERM or INCR?

Is DERM or INCR more profitable?

Does the media prefer DERM or INCR?

Which has more risk and volatility, DERM or INCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools